SANDOZ APPROVAL COULD OPEN THE FLOODGATES FOR BIOSIMILARS IN US

German biopharma firm Sandoz has won a landmark first-of its-kind biosimilar drug approval in the US after a long battle with the Food and Drug Administration (FDA). The decision could open the floodgates for generics manufacturers in this lucrative market.

In-PharmaTechnologist.com (http://www.in-pharmatechnologist.com/news/ng.asp?n=68163-sandoz-fda-biosimilar-omnitrope-follow-on-protein)